Kamble M, Gupta R, Rehan HS, Gupta LK
Research suggests that dose escalation schedules are associated with better tolerability compared to starting at a higher dose right away
Critically, to bridge the gap to real-world effects, the system would also incorporate a dynamic tier for in vivo evidence, distinguishing between effects validated in animal models versus human trials and noting known bioavailability limitations
(As a side note, I was intrigued that the control group had lower medical costs than the GLP-1 users, and materially lower medical + Rx costs, at the end of the second year regardless of the higher trend.) That total cost picture aligns more closely with my expectations and experience, but differs a lot from the headline message
Eberhardson et al., 2000) and indapamide (Hermansen et al., 1986) can all influence insulin secretory responses in vitro and in vivo in animal models
While semaglutide effectively reduces appetite in most individuals, persistent hunger can occur due to insufficient dosing duration, hormonal adaptation, dietary factors, or individual variation in medication response